Ceva Animal Health has merged all of its research and development (R&D) activities, a move that recognizes the growing importance of biotechnology and the resulting convergence of pharmaceutical and biological research. The company announced the change on September 4.

Dr. Steve Chu to lead research and development activities

To lead the consolidated activities, Ceva has appointed Dr. Steve Chu to its executive committee with responsibility for all research and development activities.


Chu joined Ceva in 2011 and has an outstanding record throughout his 30 year career in veterinary research. He previously held senior research positions with Fort Dodge, Elanco and Pfizer animal health. He is known throughout the industry for his work in developing several first-of–its kind, novel animal vaccines. Chu received the Center for Disease Control Director’s Innovation Award for his contribution to the development of an Equine West Nile virus vaccine.

Chu will remain based in the United States, where he successfully leads Ceva’s biology R&D, and will add responsibility for global pharmaceutical research to his current role. Dr. Chu’s nomination will place an accent on speed of scientific innovation and a first- hand knowledge of the United States and Chinese markets at the center of the Ceva board.